-
The independent and controllable biopharmaceutical supply chain has become a trend, and the leading pharmaceutical machine companies have attracted the attention of securities companies
Time of Update: 2022-05-23
The industry expects that the independent and controllable biopharmaceutical supply chain will become a major trend, and the leading pharmaceutical machine companies are expected to benefit in this context .
-
The tide of cooperation between pharmaceutical companies has emerged again!
Time of Update: 2022-05-23
For example, ViGeneron and Regeneron have reached a research and development cooperation on the development of a new generation of ophthalmic gene therapy; Hebo Medicine and AstraZeneca: awarded the latter to the development and commercialization of HBM7022; Cooperation with China Resources Pharma on mRNA vaccine business, etc.
-
Pfizer's JAK1 Inhibitor "Abraxitinib" Approved in China for Atopic Dermatitis
Time of Update: 2022-05-23
In September 2021, abroxitinib was approved for the first time in the UK for the treatment of adults and adolescents over 12 years of age with moderate to severe atopic dermatitis, followed by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP).
-
2022 China Elderly Living Products Exhibition/Beijing Elderly Care Products Exhibition
Time of Update: 2022-05-23
Committed to allowing more high-quality elderly products and elderly care services to enter the Chinese market, helping companies expand brand influence and expanding sales channels, and build an efficient, high-quality and accurate all-round one-stop exhibition business for exhibitors and global high-quality buyers The platform has become a "bridge" for domestic and foreign companies to explore the Chinese market .
-
Yifang Bio's new KRAS G12C inhibitor achieved positive results in Phase 1 clinical trials
Time of Update: 2022-05-23
Transfer from | Medicine GuanlanRecently, Yifang Bio announced the first clinical data of its oral KRAS G12C inhibitor in cancer patients .
This time, Yifang Bio presented its Phase 1 clinical data of its oral KRAS G12C inhibitor at the AACR .
-
The average R&D investment of domestic pharmaceutical companies has increased, and innovation is pressing the "acceleration button"!
Time of Update: 2022-05-23
From the perspective of R&D expenses, the average R&D investment of domestic pharmaceutical companies has increased, and corporate innovation has pressed the "acceleration button" .
A number of pharmaceutical companies will invest more than 1 billion yuan in research and development in 2021 .
-
The three-year period has come!
Time of Update: 2022-05-23
According to the "Administrative Measures for the National Essential Medicines List (Revised Draft)" (hereinafter referred to as the "Draft") released in November 2021 for public comments, the national essential medicines include the list of chemical drugs and biological products, the list of traditional Chinese medicines, and the list of children's medicines .
-
Another innovative medical device has been approved for marketing, and 16 have been approved during the year
Time of Update: 2022-05-23
According to the public information of the State Food and Drug Administration, the innovative medical device "Magnetic Resonance Imaging System" produced by Xingaoyi Medical Equipment Co.
According to the list, the "Magnetic Resonance Imaging System" is the 16th innovative medical device approved this year .
-
Bayer's TRK inhibitor larotrectinib approved in China
Time of Update: 2022-05-22
Today, the NMPA official website announced that the marketing application for larotrectinib (larotrectinib sulfate capsules) submitted by Bayer has been approved for the treatment of adult and pediatric patients with solid tumors carrying the NTRK fusion gene .
-
Up to $110 million!
Time of Update: 2022-05-22
LENZ is a late-stage clinical company developing innovative ophthalmic drug products that improve vision .
Acetylcridine is a small-molecule acetylcholinesterase receptor agonist that causes pupillary miosis, resulting in a pinhole effect that improves near vision .
-
Over 1 billion contrast agents!
Time of Update: 2022-05-22
com, the sales of terminal iopromide injection in Chinese public medical institutions will exceed 1 billion yuan in 2020, and the first half of 2021 will increase by more than 20% year-on-year .
-
Developing Oral mRNA Vaccines!
Time of Update: 2022-05-22
Article source: Medicine Cube ProAuthor: Bai LuOn April 11, BioNTech announced an exclusive collaboration with Matinas BioPharma to combine BioNTech's mRNA vaccine development expertise and Matinas' Lipid Nanocrystal (LNC) delivery platform technology to advance the development of new dosage forms of mRNA vaccines, including A potential formulation for an oral vaccine .
-
3rd review!
Time of Update: 2022-05-22
com, the sales of midazolam injection in China's public medical institutions will exceed 600 million yuan in 2020, with a year-on-year increase of more than 25% in the first half of 2021 .
Sales of terminal midazolam injection in Chinese public medical institutions in recent years (unit: 100 million yuan)Source: Minet.
-
BeiGene's Tislelizumab Approved for the Eighth Indication for Esophageal Squamous Cell Carcinoma
Time of Update: 2022-05-22
Screenshot source: NMPA official websiteTislelizumab is a humanized IgG4 anti-programmed death 1 (PD-1) monoclonal antibody designed to minimize binding to Fcγ receptors in macrophages .
-
Nearly 40 pharmaceutical companies disclosed their performance in the first quarter of 2022, with a high pre-happy rate
Time of Update: 2022-05-22
91% year-on-year According to the first quarter performance forecast released by Mingde Bio, the net profit attributable to shareholders of listed companies in the first quarter of 2022 is expected to be 1.
-
List of acceptance of CDE drug registration applications since 2022
Time of Update: 2022-05-21
Data source: CDE, compiled by PharmaNet (Note: based on the acceptance number, the statistical time is from January 1, 2022 to April 14, 2022) Specifically, in chemical drug registration applications, compared with 2021, this year's 2,391 chemical drugs have been accepted, accounting for about 63% of the 3,800 acceptance numbers from January to June 2021 .
-
The net profit of more than 10 pharmaceutical companies has doubled, and this company has soared more than 400 times
Time of Update: 2022-05-21
Among them, Zhifei Bio’s first quarterly report performance forecast has increased significantly, the net profit attributable to shareholders of listed companies has increased by 90%-110% year-on-year, and the profit has been 1,782,540,300 yuan to 1,970,176,100 yuan .
-
Competitive first imitation!
Time of Update: 2022-05-21
Sales of salmeterol and ticasone terminals in public medical institutions in China (unit: ten thousand yuan) Source: Minet.
Sales of salmeterol and ticasone terminals in public medical institutions in China (unit: ten thousand yuan) Source: Minet.
-
Biogen, Novartis, W Division... Who will be the next pharmaceutical company to lay off employees?
Time of Update: 2022-05-21
Judging from the financial data disclosed by major pharmaceutical companies recently, the research and development investment of many companies has increased significantly, and their technological innovation capabilities have been improved .
-
In the past week, 10 pharmaceutical companies have been investigated by institutions, and Tofflon has become the focus of attention
Time of Update: 2022-05-21
Data shows that in 2021, Betta Pharmaceuticals will invest 861 million yuan in R&D, accounting for 38.
. Haier Biology stated in the institutional survey that in 2021, the company's overseas market revenue will increase by 39.
